Copeptin Plasma Levels are Associated with Decline of Renal Function in Patients with Type 2 Diabetes Mellitus

Villela-Torres, Maria De La Luz; Higareda-Mendoza, Ana Edith; Gómez-García, Anel; Alvarez-Paredes, Alfonso Rafael; García–López, Elvia; Stenvikel, Peter; Gu, Harvest F.; Rashid-Qureshi, Abbul; Lindholm, Bengt; Álvarez-Aguilar, Cleto

doi:10.1016/j.arcmed.2018.04.002

Cited by 17 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that AVP is associated with the progression of chronic kidney disease. Plasma copeptin levels are associated with a decline in kidney function in recipients of kidney transplant [30], and high plasma copeptin levels are associated with lower GFR in patients with type II diabetes mellitus [31]. Furthermore, treatment with AVP V 1a and V 2 receptor antagonists has been shown to cause a significant reduction in blood pressure, proteinuria, and glomerulosclerosis in animal models with 5/6 nephrectomy [32].…”

Section: Discussionmentioning

confidence: 99%

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

et al. 2021

View full text Add to dashboard Cite

Background Tolvaptan slowed the rates of total kidney volume (TKV) growth and renal function decline over a 3-year period in patients with autosomal dominant polycystic kidney disease (ADPKD) enrolled in the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial (NCT00428948). In this post hoc analysis of Japanese patients from TEMPO 3:4, we evaluated whether the effects of tolvaptan on TKV and on renal function are interrelated. Methods One hundred and forty-seven Japanese patients from TEMPO 3:4 were included in this analysis (placebo, n = 55; tolvaptan, n = 92). Tolvaptan-treated patients were stratified into the responder group (n = 37), defined as tolvaptan-treated patients with a net decrease in TKV from baseline to year 3, and the non-responder group (n = 55), defined as tolvaptan-treated patients with a net increase in TKV. Results Mean changes during follow-up in the placebo, responder, and non-responder groups were 16.99%, − 8.33%, and 13.95%, respectively, for TKV and − 12.61, − 8.47, and − 8.58 mL/min/1.73 m2, respectively, for estimated glomerular filtration rate (eGFR). Compared with the placebo group, eGFR decline was significantly slowed in both the responder and non-responder groups (P < 0.05). Conclusion Tolvaptan was effective in slowing eGFR decline, regardless of TKV response, over 3 years in patients with ADPKD in Japan. Treatment with tolvaptan may have beneficial effects on slowing of renal function decline even in patients who have not experienced a reduction in the rate of TKV growth by treatment with tolvaptan.

show abstract

Section: Discussionmentioning

confidence: 99%

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In recent years, several studies have provided strong evidence that increased levels of copeptin are linked to diabetic macro-and microvascular complications [36][37][38][39].…”

Section: Copeptin and Diabetic Complicationsmentioning

confidence: 99%

Copeptin as a novel biomarker of cardiometabolic syndrome

Szmygin

Szydełko

Matyjaszek‐Matuszek

2021

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…The possible role of chronic vasopressin secretion in the incidence and progression of diabetic and non-diabetic CKD has been recently highlighted in various clinical [8,9,10,11,12] and experimental studies [7,13]. Chronic stimulation and/or overexpression of vasopressin receptors V1a and V2 have been associated with renal and cardiac alterations, while chronic blockade of both receptors has provided beneficial effects [14,15,16].…”

Section: Introductionmentioning

confidence: 99%

A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose

García-Arroyo

Muñoz-Jiménez

Gonzaga

et al. 2019

IJMS

View full text Add to dashboard Cite

Chronic vasopressin secretion induced by recurrent mild heat stress exposure is significantly enhanced by limited rehydration with a fructose-containing beverage both in rodents and in humans. Moreover, this effect has been associated with upregulation of the polyol–fructokinase pathway and increased renal oxidative stress. Previously, we have shown that pharmacological inhibition of both V1a and V2 vasopressin receptors with conivaptan improved such renal alterations. The aim of this study was to evaluate the independent contributions of V1a and V2 receptors to the renal damage caused by mild heat stress and limited rehydration with a fructose-containing beverage. Osmotic minipumps were used to deliver either relcovaptan (0.64 mg/day) or tolvaptan (0.25 mg/day) in male Wistar rats for two weeks. Corresponding dilution vehicles were used as controls. To induce dehydration, rats were exposed to mild heat stress (37 °C for 1 h, Monday to Friday). All groups received a 10% fructose solution as a rehydration fluid for 2 h after mild heat stress. For the remainder of the day and on weekends, rats received tap water. The independent blockade of either the V1a or the V2 receptor prevented renal damage, reduced oxidative stress, and decreased plasma cortisol and systemic inflammation. However, the beneficial effects were regulated by different mechanisms. Tolvaptan inhibited polyol–fructokinase pathway overactivation, while relcovaptan prevented upregulation of the renin–angiotensin system and SGK1 expression. These data suggest that both V1a and V2 receptors participate in renal damage caused by heat stress-induced dehydration when fructose-containing beverages are used as rehydration fluids.

show abstract

Copeptin Plasma Levels are Associated with Decline of Renal Function in Patients with Type 2 Diabetes Mellitus

Cited by 17 publications

References 34 publications

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

Copeptin as a novel biomarker of cardiometabolic syndrome

A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose

Contact Info

Product

Resources

About